AbbVie Inc (NYSE:ABBV), the pharmaceutical research company indicated that their experimental drug for leukemia performed well in early stage one clinical traits. More than 80 percent of the patients who took the drug (ABT-199) saw positive results. For example, the drug either reduced or eliminated signs of the leukemia. In phase I, 67 patients were tested. The main purpose of ABT-199 is to restore the body’s natural mechanism to kill or fight bad cells by blocking the protein BCL-2, which prevents that natural process from occurring.